A full suite of bioanalytical capabilities including:
- Preclinical bioanalysis and PK studies
- First-in-human and dose-escalation studies
- Bioanalytical methods for human clinical PK
- Clinical pharmacology
- Bioavailability and bioequivalence
- PK/PD support and clinical pharmacology
- Biomarkers and drug–drug interactions
- Elemental impurity analysis (ICH Q3) – ICP-MS
- Nitrosamine
Advanced bioanalytical instrumentation and on-site technologies:
- UPLC-MS/MS, LC-MS/MS, LC-HR-MS
- LC-TRAP-MS, LC-QTOF-MS
- LC-ICP-MS/MS, ICP-MS, ICP-MS/MS
- GC-MS, GC-MS/MS
Arcinova: Your partner for bioanalytical services
Tailored bioanalysis services backed by decades of experience
Every programme is unique – and so is our response. With over 40 years of experience and more than 500 validated methods, our team delivers tailored, phase-appropriate bioanalytical support across a wide range of analytes, including small molecules, proteins, and volatile compounds. We adapt quickly to the needs of each study, helping you generate the insights you need, faster.
Scientifically robust, compliant data you can trust
Our GLP and GCP-accredited bioanalytical facilities are purpose-built to support studies from discovery to late-stage clinical. Equipped with advanced instrumentation and Class II and III biosafety containment, we generate decision-ready data you can rely on for regulatory submissions, audits, and confident next steps.
Highly sensitive assays optimised for your programme
We develop and validate highly selective assays for quantifying analytes from small-volume biological samples – often down to pg/mL concentrations. Our scientists ensure assay performance is aligned with study needs, and fully compliant with ICH M10, EMA and FDA guidelines.
Fast-tracking your molecule from candidate selection to clinic with integrated expertise in drug substance process development, scale-up, and manufacturing.
Arcinova act as an IND/IMPD launchpad, specializing in progressing molecules from preclinical candidate selection to GMP manufacture for first-in-human trials. We holistically consider the synthetic route, molecular properties and regulatory strategy to minimize risk and accelerate delivery of complex drug development programs so you can move confidently from lab to clinic.
What our customers have to say about working with us:
PLACEHOLDER FOR CLIENT TESTIMONIAL
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla sit amet vulputate enim, at blandit est. Maecenas eget convallis urna, a consequat magna. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
